Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen

Leuk Res. 2021 Jul:106:106583. doi: 10.1016/j.leukres.2021.106583. Epub 2021 Apr 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow / pathology
  • Gemtuzumab / administration & dosage
  • Humans
  • Neoplasm Staging
  • Sarcoma, Myeloid / drug therapy*
  • Sarcoma, Myeloid / pathology*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Gemtuzumab